Clinical Trials on Gastrointestinal Adenocarcinomas

Total 31214 results

Trans Tasman Radiation Oncology Group
Australasian Gastro-Intestinal Trials Group; Colorectal Surgical Society of... and other collaborators

Completed

A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum

Adenocarcinoma of Rectum

Australia, New Zealand
Amgen

Completed

Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma

Gastrointestinal Cancer
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); ECOG-ACRIN Cancer Research Group

Withdrawn

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Gastrointestinal Cancer | Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Adenocarcinoma of the Esophagus | Stage IV Esophageal Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric... and other conditions

United States
University of Nebraska
National Cancer Institute (NCI)

Terminated

Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer

Esophageal Adenocarcinoma | Adenocarcinoma of the Gastroesophageal Junction | Stage IIB Esophageal Cancer | Stage IIA Esophageal Cancer

United States
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment

Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment)

Spain
Massachusetts General Hospital
Ipsen

Recruiting

Folfox+Irinotecan+Chemort In Esophageal Cancer

Esophagogastric Cancer | Gastroesophageal Junction Adenocarcinoma

United States
Hoffmann-La Roche

Terminated

A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Stomach Neoplasms | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Active, not recruiting

Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer

Colorectal Adenocarcinoma

United States
Ipsen

Withdrawn

Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.

Colorectal Cancer | Pancreatic Ductal Adenocarcinoma

Belgium, France
The First Affiliated Hospital of Xiamen University

Unknown

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

Locally Advanced or Metastatic Gastric Adenocarcinoma

China
Associacio catalana per a la recerca oncologica...
Hoffmann-La Roche

Unknown

XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

Rectal Neoplasms | Locally Advanced Rectal Adenocarcinoma

Spain
Fujian Cancer Hospital

Unknown

Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA

Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

China
National Health Research Institutes, Taiwan
China Medical University Hospital; Chang Gung Memorial Hospital; Kaohsiung Medical... and other collaborators

Not yet recruiting

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

Chemotherapy | Metastatic Gastric Adenocarcinoma | Second Line
Wuhan Union Hospital, China

Recruiting

Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer

Colorectal Adenocarcinoma

China
Chinese PLA General Hospital

Recruiting

Transhiatal/Transabdominal Approach Compare With Thoracoabdominal Approach for Siewert II Adenocarcinoma of Esophagogastric Junction

Adenocarcinoma of Esophagogastric Junction

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer (SOLARIS)

Colorectal Adenocarcinoma

United States, Puerto Rico
Providence Health & Services
Eli Lilly and Company

Active, not recruiting

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

Rectal Adenocarcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute

Completed

Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma

Rectal Cancer | Rectal Adenocarcinoma

United States
Michael Patrick Achiam

Completed

Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer

Esophagus Cancer, Adenocarcinoma

Denmark
Peking University
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

China
University of Manchester
The Christie NHS Foundation Trust

Unknown

Optimisation of Radiotherapy in Rectal Cancer (ORREC) (ORREC)

Rectal Adenocarcinoma

United Kingdom
Cliniques universitaires Saint-Luc- Université...

Completed

Interest of Saline MR Peritoneography for Pre-operative Assessment of Rectal Cancer

Rectal Adenocarcinoma

Belgium
Johannes Gutenberg University Mainz
AIO-Studien-gGmbH

Completed

Efficacy of Cetuximab in Combination With Irinotecan and 5- FU/FA in Treatment of Metastatic Gastric Cancer (GC-CIF-2005)

Adenocarcinoma of Stomach or Esophagogastric Junction

Germany
University of Southampton
Bristol-Myers Squibb

Recruiting

Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer (ELEVATE)

Cancer of Esophagus | Adenocarcinoma - GEJ

United Kingdom
AHS Cancer Control Alberta

Not yet recruiting

A Phase II Trial of iTTo in Advanced Gastric and GEJ Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma | Advanced Gastric Carcinoma

Canada
National Cancer Centre, Singapore

Recruiting

Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma

Colorectal Cancer | Pancreatic Adenocarcinoma

Singapore
University of Campania "Luigi Vanvitelli"

Active, not recruiting

caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer. (ABACO)

Refractory Colorectal Adenocarcinoma

Italy
Eli Lilly and Company

No longer available

Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma
Assiut University

Completed

Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted Therapy (EGFR)

Metastatic Colorectal Adenocarcinoma
Daiichi Sankyo
AstraZeneca

Recruiting

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Gastroesophageal Junction Adenocarcinoma | Gastric Cancer, Adenocarcinoma

Italy, Hong Kong, Belgium, Korea, Republic of, France, United Kingdom, Spain, China, Ireland, Brazil, Japan, Singapore, Israel, Russian Federation, Argentina, Chile, Hungary, Poland, Portugal, Taiwan, Turkey, Ukraine, Germany, Romania
Castle Biosciences Incorporated

Terminated

Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays

Anal Squamous Cell Carcinoma | Rectal Adenocarcinoma | Anal Adenocarcinoma

United States
Fujian Cancer Hospital

Unknown

mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

China
AIO-Studien-gGmbH
Neovii Biotech

Completed

Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas (CatuNeo)

Gastric Adenocarcinoma With Peritoneal Carcinomatosis | Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis | Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis

Germany
National Cancer Institute (NCI)

Completed

Edrecolomab in Treating Patients With Stage II Colon Cancer

Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Stage IIA Colon Cancer | Stage IIB Colon Cancer | Stage IIC Colon Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IV Colon Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Unresectable Colon Adenocarcinoma | Unresectable Rectal Adenocarcinoma

United States, Puerto Rico
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colon Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma

United States
Vall d'Hebron Institute of Oncology

Active, not recruiting

Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) (MONEO)

Stomach Neoplasms | Gastroesophageal Junction Adenocarcinoma

Spain
West China Hospital

Recruiting

Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors

Recurrence | Stomach Neoplasms | Siewert Type II Adenocarcinoma of Esophagogastric Junction | Siewert Type III Adenocarcinoma of Esophagogastric Junction

China
Case Comprehensive Cancer Center

Active, not recruiting

FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma

Adenocarcinoma of the Gastroesophageal Junction | Adenocarcinoma of the Esophagus | Stage IIIA Esophageal Cancer | Stage IIIB Esophageal Cancer | Stage IIIC Esophageal Cancer | Adenocarcinoma of the Gastric Cardia

United States
Fudan University

Recruiting

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer (Miracle-G)

Adenocarcinoma | Metastatic Cancer | Metastatic Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Oligometastatic Disease | Stomach Neoplasm | Adenocarcinoma of the Stomach | Gastroesophageal-junction Cancer | Metastatic Adenocarcinoma

China
Ruihua Xu

Recruiting

Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma

China
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

HER2-positive Advanced Gastric Cancer | HER2-positive Gastroesophageal Junction Adenocarcinoma

Austria, Belgium, Germany, Italy
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer | Gastric Adenocarcinoma | Esophagogastric Cancer | Gastroesophageal Junction Adenocarcinoma | Esophagus Cancer | Gastroesophageal Junction Squamous Cell Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC; Genentech, Inc.

Recruiting

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Esophageal Cancer | Gastric Adenocarcinoma | HER2 Gene Mutation

United States
University College, London
University College London Hospitals; Merck Sharp & Dohme LLC; University of Leeds and other collaborators

Recruiting

NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer (NEOPRISM-CRC)

Adenocarcinoma of the Colon

United Kingdom
National Cheng-Kung University Hospital
China Medical University Hospital; Taipei Veterans General Hospital, Taiwan; Kaohsiung... and other collaborators

Recruiting

Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer (LOTS)

Gastric Cancer | Gastric Adenocarcinoma | Toxicity Due to Chemotherapy | Effects of Chemotherapy

Taiwan
Washington University School of Medicine

Active, not recruiting

Non-Operative Management and Early Response Assessment in Rectal Cancer (NOM-ERA)

Adenocarcinoma of the Lower Rectum

United States
National Cancer Institute (NCI)

Active, not recruiting

Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology

Gastric Cancer | Gastric Adenocarcinoma | Esophagogastric Junction

United States
University of Texas Southwestern Medical Center
Apexigen America, Inc.

Active, not recruiting

INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer

Locally Advanced Rectal Adenocarcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy

Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States

Clinical Trials on Gastrointestinal Adenocarcinomas

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations